Feedback

Resources

HCP communities and education

PsychU

PsychU is a community for mental health professionals dedicated to improving care through information, discussion, and collaboration. At PsychU, you may access resources on the latest mental health-care developments, treatment best practice guidelines, and more.

Global Council on Alzheimer’s Disease (GCAD)

Otsuka launched the GCAD collaboration group with a focus on patient-centered care. The community includes leaders and influencers from advocacy groups, healthcare professionals, academics, and leaders from financial institutions. Participants share knowledge and ideas at educational summits as part of an ongoing effort to determine the best ways to work together to meet patients’ needs.

NephU

NephU is a growing community where nephrology healthcare professionals engage, collaborate, and utilize resources to help improve future outcomes for those with kidney disease and other related conditions. At NephU, you may access resources related to kidney diseases, nutrition, diagnostic tools, and more.

PhactMI

PhactMI is a collaboration of pharmaceutical company Medical Information departments that are dedicated to supporting healthcare professionals in their commitment to provide quality patient care

Additional HCP resources

Other external links

Publications

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study

Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study

A randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting injectable in adults with schizophrenia or bipolar I disorder

Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial

Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study

Patient resources

Care and Financial Support

Explainer text about this resource..

Otsuka Patient Education Network (OPEN)

Explainer text about this resource..

Affordability Assistance

Explainer text about this resource..

Contact us

Submit a medical inquiry

Submit a medical question on an Otsuka product.

Contact center support

To discuss a medical inquiry on an Otsuka product, please call 1-800-441-67631-800-441-6763.

Report an adverse event or product complaint

To report an adverse event or a product quality complaint, please call 1-800-438-99271-800-438-9927.